List view / Grid view
13 November 2014 | By Frost & Sullivan
Cloud service providers that offer guaranteed reliability and clear data portability terms will emerge as top contenders, finds Frost & Sullivan...
13 November 2014 | By British Generic Manufacturers Association
Price cuts for branded generic medicines as part of proposed Government changes to the statutory scheme to control the prices of branded health service medicines will undermine innovation, create uncertainty, reduce competition and ultimately undermine patient benefits...
13 November 2014 | By ABIVAX
ABIVAX, a leading European, clinical stage biopharmaceutical company developing and commercializing anti-viral compounds and human vaccines, announced that it has signed an agreement with The Finlay Institute, Havana, Cuba...
12 November 2014 | By TiGenix NV
TiGenix NV announced that it has completed the patient recruitment for its Phase III trial of Cx601 in Europe for the treatment of complex perianal fistulas in Crohn's patients...
12 November 2014 | By GlobalData
Biologics will play an influential role in shaping the future of cardiovascular (CV) drug treatment, as these and other emerging therapies will compete for patients who cannot tolerate statins, or for whom statin therapy alone is insufficient, according to an analyst with research and consulting firm GlobalData...
12 November 2014 | By Novartis
Novartis announced that, through Power of One, enough funds have been raised to deliver three million antimalarial treatments for children in Zambia...
11 November 2014 | By Mundipharma
New research unveiled by Mundipharma highlights inconsistencies in health economic models and measurement methods used in clinical trials for pain therapies...
The newest GLP-1 receptor agonist treatment option to help improve glycemic control type 2 diabetes in adults is now available in U.S. pharmacies. Eli Lilly and Company's (LLY) Trulicity™ (dulaglutide) is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed with patients in mind. It comes in a single-dose pen…
11 November 2014 | By Moberg Pharma
In accordance with the resolution of the Annual General Meeting on May 13, 2014, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee...
11 November 2014 | By The Centre for Process Innovation
The Centre for Process Innovation (CPI) is part of a consortium which will focus on the development and scale up of nanopharmaceutical production...
11 November 2014 | By Janssen
Compared with their peers and other caregivers, carers for adults with schizophrenia report deteriorated physical and mental health and greater health resource usage/utilisation...
10 November 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced late-breaking data from the landmark ALLY Trial investigating a ribavirin-free 12-week regimen of daclatasvir (DCV) in combination with sofosbuvir (SOF) in genotype 3 hepatitis C (HCV) patients, a patient population that has emerged as one of the most difficult to treat...
10 November 2014 | By Genmab A/S
Genmab A/S announced today that the French Intergroup of Myeloma (IFM) in collaboration with Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and Janssen Biotech, Inc. plans to start an additional Phase III study of daratumumab in frontline multiple myeloma...
10 November 2014 | By Almirall
Almirall, the global pharmaceutical company based in Barcelona, announced year to date 2014 results...
10 November 2014 | By KU Leuven
A new drug combination for rheumatoid arthritis treats the disease just as well as other intensive treatment strategies but with less medication and fewer side effects at a significantly lower cost...
